Advertisement
Editorial Comment| Volume 29, ISSUE 3, P255-257, March 2023

Moving Toward “Precision” Medicine: Can We Tailor Diabetes Therapy to Patients’ Differential Risks of Future Cardiovascular Disease?

Published:December 15, 2022DOI:https://doi.org/10.1016/j.cardfail.2022.12.002
      Cardiovascular disease (CVD) and diabetes (DM) can be thought of as twin epidemics, and the diagnosis of one dramatically increases the risk of developing the other. This risk has been well described, dating back half a century. In the late 1970s, the foundational Framingham study documented a 2–3-fold increased risk of atherosclerotic cardiovascular disease (ASCVD) in individuals with DM.
      • Kannel WB
      • McGee DL.
      Diabetes and cardiovascular disease. the Framingham Study.
      This increased risk holds true in heart failure (HF) as well.
      • Kenny HC
      • Abel ED.
      Heart failure in type 2 diabetes mellitus.
      Looking forward, given the aging of the population and the increasing prevalence of urbanization, obesogenic diets and sedentary lifestyles, the incidence of DM, as well as ASCVD and HF, will only continue to rise.
      • Fan W.
      Epidemiology in diabetes mellitus and cardiovascular disease.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Kannel WB
        • McGee DL.
        Diabetes and cardiovascular disease. the Framingham Study.
        JAMA. 1979; 241: 2035-2038https://doi.org/10.1001/jama.241.19.2035
        • Kenny HC
        • Abel ED.
        Heart failure in type 2 diabetes mellitus.
        Circ Res. 2019; 124: 121-141https://doi.org/10.1161/circresaha.118.311371
        • Fan W.
        Epidemiology in diabetes mellitus and cardiovascular disease.
        Cardiovasc Endocrinol. 2017; 6: 8-16https://doi.org/10.1097/xce.0000000000000116
        • Randhawa VK
        • Dhanvantari S
        • Connelly KA.
        How diabetes and heart failure modulate each other and condition management.
        Can J Cardiol. 2021; 37: 595-608https://doi.org/10.1016/j.cjca.2020.11.014
        • Sheahan KH
        • Wahlberg EA
        • Gilbert MP.
        An overview of GLP-1 agonists and recent cardiovascular outcomes trials.
        Postgrad Med J. 2020; 96: 156-161https://doi.org/10.1136/postgradmedj-2019-137186
        • Davies MJ
        • Aroda VR
        • Collins BS
        • Gabbay RA
        • Green J
        • Maruthur NM
        • et al.
        Management of hyperglycemia in type 2 diabetes, 2022. a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
        Diabetes Care. 2022; 45: 2753-2786https://doi.org/10.2337/dci22-0034
        • Balkan L
        • Ringel JB
        • Levitan EB
        • Khodneva YA
        • Pinheiro LC
        • Sterling MR
        • et al.
        Association of Perceived Stress With Incident Heart Failure.
        J Card Fail. 2022; 28: 1401-1410https://doi.org/10.1016/j.cardfail.2022.04.013
        • Arnett DK
        • Blumenthal RS
        • Albert MA
        • Buroker AB
        • Goldberger ZD
        • Hahn EJ
        • et al.
        2019 ACC/AHA Guideline on the Primary Prevention of Cardiovascular Disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.
        Circulation. 2019; 140: e596-e646https://doi.org/10.1161/cir.0000000000000678
        • Hong YR
        • Mainous 3rd, AG
        Development and validation of a county-level social determinants of health risk assessment tool for cardiovascular disease.
        Ann Fam Med. 2020; 18: 318-325https://doi.org/10.1370/afm.2534